USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
In California, an artificial intelligence-based protein design company called Profluent has added $35 million to its financing, with money being put forward by Spark Capital, among others. 25 March 2024
The biobanking market - valued at $60.74 billion in 2022 - is forecast to grow at a CAGR of 5.68%, reaching a market size of $89.41 billion by 2029. 21 March 2024
Swiss pure-play dermatology category leader Galderma Group today announced the pricing of its Initial Public Offering (IPO) at 53 Swiss francs per share, at the top of the announced price range.
The shares will 21 March 2024
Capstan Therapeutics, a company advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles, has become the latest San Diego biotech to announce a major fundraising. 21 March 2024
Another start-up has launched in the bustling biotech hub around Boston, USA, with $150 million in financing from investors including Novo Holdings. 21 March 2024
Angelini Ventures has announced its participation in an extension of the Series C financing round for Swiss immuno-oncology firm Nouscom. 21 March 2024
Madrigal Pharmaceuticals saw its shares close down 6.2% at $265.68 yesterday, after it announced the pricing of its underwritten public offering of 750,000 shares of its common stock. 20 March 2024
San-Diego Contineum Therapeutics, biotech developing small molecule therapies for the treatment of neuroscience, inflammation, and immunology (NI&I) indications, is going public. 19 March 2024
Samsung Life Science Fund announced Samsung’s investment in Boston, USA-based BrickBio, a pre-clinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code. 19 March 2024
In the UK, research originating from Cambridge University has received a significant vote of confidence from investors banking on the therapeutic potential of mitochondria. 18 March 2024
New York-based neuroscience company Gilgamesh Pharmaceuticals has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA). 14 March 2024
German antibody drug conjugate (ADC) specialist Tubulis has announced the successful completion of an upsized and oversubscribed 128 million euros ($138.8 million) Series B2 financing. 14 March 2024
The biopharmaceutical industry is witnessing a shift in investor sentiment. Despite facing challenges such as declining venture financing and macroeconomic pressures, there exists optimism about a recovery in biotech funding. 13 March 2024
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news